A Mechanistic, Enantioselective, Physiologically Based Pharmacokinetic Model of Verapamil and Norverapamil, Built and Evaluated for Drug–Drug Interaction Studies

A Mechanistic, Enantioselective, Physiologically Based Pharmacokinetic Model of Verapamil and Norverapamil, Built and Evaluated for Drug–Drug Interaction Studies

The calcium channel blocker and antiarrhythmic agent verapamil is recommended by the FDA for drug–drug interaction (DDI) studies as a moderate clinical CYP3A4 index inhibitor and as a clinical Pgp inhibitor. The purpose of the presented work was to develop a mechanistic whole-body physiologically ba...

Full description

Bibliographic Details
Main Authors: Nina Hanke, Denise Türk, Dominik Selzer, Sabrina Wiebe, Éric Fernandez, Peter Stopfer, Valerie Nock, Thorsten Lehr
Format: Article
Language:English
Published: MDPI AG 2020-06-01
Series:Pharmaceutics
Subjects:
physiologically based pharmacokinetic (PBPK) modeling
verapamil
norverapamil
drug–drug interactions (DDIs)
cytochrome P450 3A4 (CYP3A4)
P-glycoprotein (Pgp)
Online Access:https://www.mdpi.com/1999-4923/12/6/556

Internet

https://www.mdpi.com/1999-4923/12/6/556

Similar Items